When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

This review aims to provide an extensive overview of the literature on the clinical
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …

This article summarizes part of a consensus meeting about mycophenolate (MPA)
therapeutic drug monitoring held in Rome under the auspices of The Transplantation …

Abstract Background and Objective Valproic acid (VPA) follows a non-linear
pharmacokinetic profile in terms of protein-binding saturation. The total daily dose regarding …

Mycophenolic acid (MPA), the active drug moiety of mycophenolate, is a potent
immunosuppressant agent, which is increasingly being used in the treatment of patients with …

Immunosuppressive therapy is pivotal for sustained allograft and patient survival after renal
transplantation. However, optimally balanced immunosuppressive therapy is challenged by …

Aims Pharmacokinetic studies of the immunosuppressive compound mycophenolic acid
(MPA) have shown a structural decrease in clearance (CL) over time after renal …

With the increasing use of mycophenolic acid (MPA) as an immunosuppressant in solid
organ transplantation and in treating autoimmune diseases such as systemic lupus …

Several factors contribute to mycophenolic acid (MPA) between-patient variability. Here we
characterize the metabolic pathways of MPA and quantify the effect of combining genetic …

Abstract Background and Objectives No evaluation of sex and race influences on
mycophenolic acid (MPA) pharmacokinetics and adverse effects (AEs) during enteric-coated …